Anecortave acetate as monotherapy for treatment of subfoveal neovascularization in age-related macular degeneration: twelve-month clinical outcomes

To evaluate safety and efficacy of the angiostatic agent anecortave acetate, compared with a placebo, for treatment of subfoveal choroidal neovascularization (CNV). Ongoing masked, randomized, placebo-controlled, parallel evaluation of anecortave acetate (30 mg, 15 mg, and 3 mg) versus a placebo. Th...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Ophthalmology (Rochester, Minn.) Minn.), 2003-12, Vol.110 (12), p.2372-2383
Hauptverfasser:	D'Amico, Donald J, Goldberg, Morton F, Hudson, Henry, Jerdan, Janice A, Krueger, D Scott, Luna, Susan P, Robertson, Stella M, Russell, Stephen, Singerman, Lawrence, Slakter, Jason S, Yannuzzi, Lawrence, Zilliox, Patricia
Format:	Artikel
Sprache:	eng
Schlagworte:	Aged Aged, 80 and over Angiogenesis Inhibitors - therapeutic use Choroidal Neovascularization - diagnosis Choroidal Neovascularization - drug therapy Choroidal Neovascularization - etiology Coloring Agents Double-Blind Method Drug Evaluation Female Fluorescein Angiography Follow-Up Studies Fovea Centralis Humans Indocyanine Green Macular Degeneration - complications Macular Degeneration - diagnosis Macular Degeneration - drug therapy Male Pregnadienediols - therapeutic use Prospective Studies Safety Treatment Outcome Visual Acuity
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!